ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Disagree

<< Previous

Bullboard Posts

Next >>

Comment by Thenorth1990on Oct 13, 2021 1:40pm

197 Views

Post# 34001886

RE:Disagree

I have always agreed with Nasdaq move , The question is what price, Secondly will it fall 75% to $1, the tale of majority of small cap biotech , so I am thinking most companies do not want o start at the min bid price, I am happy to to have lesser shares reversed but expecting fmuch higher. Cheers

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property